C0737
Cilostazol
≥98% (HPLC), Phosphodiesterase III (PDE3) inhibitor, powder
Sinónimos:
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone, OPC 13013, OPC 21, Pletaal
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
Fórmula empírica (notación de Hill):
C20H27N5O2
Número CAS:
Peso molecular:
369.46
UNSPSC Code:
41106305
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleNombre del producto
Cilostazol, ≥98% (HPLC), powder
Quality Level
assay
≥98% (HPLC)
form
powder
color
off-white
solubility
DMSO: 10 mg/mL, clear
originator
Otsuka Pharma
SMILES string
O=C1CCc2cc(OCCCCc3nnnn3C4CCCCC4)ccc2N1
InChI
1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
InChI key
RRGUKTPIGVIEKM-UHFFFAOYSA-N
Gene Information
human ... PDE3A(5139), PDE3B(5140)
General description
Cilostazol prevents platelet aggregation and has vasodilatory properties. It is used to treat chronic arterial disease and intermittent claudication. Cilostazol has antiproliferative effects and improves the properties of prostacyclin. It regulates cell proliferation, stimulates cyclic adenosine monophosphate (cAMP) level and induces cyclic AMP-dependent protein kinase.
Application
Cilostazol has been used:
- to reduce Madin–Darby cell line (MDCK) proliferation through c-Myc down-regulation
- in the in vitro assessment of toxin delivery in T84 intestinal epithelial cells
- to induce adenosine triphosphate (ATP) release in white adipocytes
Biochem/physiol Actions
Phosphodiesterase III (PDE3) inhibitor
Features and Benefits
This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Otsuka Pharma. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Repr. 2
Clase de almacenamiento
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Pannexin-1 mediated ATP release in adipocytes is sensitive to glucose and insulin and modulates lipolysis and macrophage migration
Tozzi M, et al.
bioRxiv, 380469-380469 (2018)
Kuang-Yi Tseng et al.
Medicina (Kaunas, Lithuania), 59(3) (2023-03-30)
Background and Objective: Our previous study demonstrated that consistent treatment of oral cilostazol was effective in reducing levels of painful peripheral neuropathy in streptozotocin-induced type I diabetic rats. As diabetic neuropathy is characterized by hyperglycemia-induced nerve damage in the periphery
Cilostazol reduces proliferation through c-Myc down-regulation in MDCK cells
Munoz B, et al.
European Journal of Pharmacology, 616(1-3), 22-30 (2009)